Updated:
Harrington Discovery Institute
The Harrington Discovery Institute was founded with capital from an undisclosed family office, structured to accelerate drug development from academic...
Harrington Discovery Institute
The Harrington Discovery Institute was founded with capital from an undisclosed family office, structured to accelerate drug development from academic labs. It operates from offices in New York and London, reflecting a transatlantic reach in biomedical research funding. The institute's strategy centers on funding early-stage discoveries — typically at the preclinical or proof-of-concept stage — with the goal of advancing them through to clinical trials. It provides grants and scientific support to principal investigators at universities, focusing on areas such as rare diseases, oncology, and neurology. The model resembles a venture philanthropy approach, where returns are measured in therapeutic impact rather than financial returns. Team size remains undisclosed, but the institute is led by a scientific advisory board drawn from major research institutions. No recent operational events have been publicly reported in the last 24 months. The institute's structure positions it as a hybrid between a charitable foundation and an early-stage biotech incubator. A key structural differentiator is the institute's reliance on a single-family-office backer, which sets it apart from typical NIH-funded academic-medicine initiatives or venture-capital-backed biotechs. This capital source allows longer investment horizons and a tolerance for scientific risk that commercial VCs often avoid.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York, London
Corporate office
New York, NY, United States
Additional offices
London, United Kingdom
Sector focus
Frequently asked questions
Who runs the investment decisions at the Harrington Discovery Institute?
The institute is overseen by a scientific advisory board that includes researchers from institutions such as Case Western Reserve University. Direct investment decisions are made by the institute's leadership, which has not been publicly named. The family office backer provides capital but does not publicly interfere in scientific direction.
How does the Harrington Discovery Institute source deal flow?
Deal flow comes primarily through academic partnerships, where the institute solicits grant applications from university researchers. It does not accept unsolicited pitches from startups. The institute's scientific advisory board reviews proposals based on therapeutic potential and feasibility.
Is the Harrington Discovery Institute structured as a family office or a venture firm?
It is structured as a grant-making entity funded by a single family office, not a traditional venture firm. It does not seek financial returns — success is defined by advancing drugs to clinical trials. This structure allows it to fund projects with high scientific risk that commercial VCs might reject.
What is the relationship between the Harrington Discovery Institute and the family office that backs it?
The family office provides capital to the institute as a philanthropic vehicle. The institute operates independently in its scientific decision-making, with the family office receiving no direct financial return. This separation is typical of family-office philanthropic arms.
Does the institute fund only academic projects or commercial entities too?
The institute primarily funds academic projects through grants to principal investigators. It does not make equity investments in startups or take board seats. The funding is structured as non-dilutive grants, typically between $100,000 and $500,000 per project.
Which therapeutic areas does the Harrington Discovery Institute focus on?
The institute targets drug development for rare diseases, oncology, neurology, and genetic disorders — areas where academic discoveries face high failure rates and limited commercial funding. It avoids areas with abundant private-sector investment, such as diabetes or common cancers.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: